Skin Diseases, Genetic: Clinical Trials

1389 completed, 275 recruiting, 250 unknown, 165 terminated. 594 Phase 2, 531 Not applicable, 322 Phase 3, 319 Phase 1, 160 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	594	Completed 369, Terminated 71, Recruiting 56, Unknown 34, Active not recruiting 27, Not yet recruiting 18, Withdrawn 15, Enrolling by invitation 4
Not applicable	531	Completed 295, Unknown 85, Recruiting 55, Terminated 30, Not yet recruiting 28, Withdrawn 18, Active not recruiting 14, Enrolling by invitation 6
Phase 3	322	Completed 200, Recruiting 31, Active not recruiting 21, Not yet recruiting 18, Unknown 18, Terminated 16, Withdrawn 13, Enrolling by invitation 3, Suspended 2
Phase 1	319	Completed 207, Recruiting 34, Terminated 32, Unknown 19, Withdrawn 11, Not yet recruiting 8, Active not recruiting 6, Enrolling by invitation 2
Phase 4	160	Completed 95, Unknown 20, Terminated 14, Not yet recruiting 11, Recruiting 8, Active not recruiting 6, Withdrawn 5, Enrolling by invitation 1
Early Phase 1	23	Completed 12, Recruiting 3, Active not recruiting 2, Terminated 2, Unknown 2, Enrolling by invitation 1, Withdrawn 1

Follow Skin Diseases, Genetic: new trials by email Literature Review of Skin Diseases, Genetic trials Research Report on Skin Diseases, Genetic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma	Phase 1 / Phase 2	Not yet recruiting	Northwestern University	44	2027-07-01	2026-08-03
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis	Phase 2	Not yet recruiting	Enzychem Lifesciences Corporation	150	2027-05-01	2026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Pfizer	90	2027-05-01	2026-09-16
An Exercise and Lifestyle Programme for Adults With Vascular Ehlers-Danlos Syndrome: A Feasibility Study Co-designed exercise-based lifestyle intervention - Vascular Ehlers Danlos Syndrome	Not applicable	Not yet recruiting	Sheffield Hallam University	40	2027-03-01	2026-07-13
Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)	Phase 1 / Phase 2	Not yet recruiting	Manhattan Pain Medicine, PLLC	100	2027-01-15	2026-10-06
Educational Eczema Video Intervention in-clinic video intervention, at home video intervention - Eczema	Not applicable	Withdrawn	Boston Children's Hospital		2027-01-01	2026-10-19
Allergy, Asthma, and Atopic Eczema in Finland No intervention, No Intervention: Observational Cohort - Asthma, Asthma in Children		Not yet recruiting	Tampere University	1200000	2026-12-01	2026-10-15
Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis	Phase 4	Not yet recruiting	Wake Forest University Health Sciences	50	2026-12-01	2026-09-04
An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%) - Epidermolysis Bullosa (EB)	Phase 3	Not yet recruiting	Paradigm Therapeutics	80	2026-11-15	2026-09-09
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis	Phase 4	Not yet recruiting	Forefront Dermatology S.C	250	2026-11-11	2026-10-02
Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds Non-conforming pz-cel surgical application to RDEB wounds, Additional biopsies, Pz-cel surgical application to DEB wounds - Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Phase 4	Not yet recruiting	Abeona Therapeutics, Inc	100	2026-11-01	2026-08-06
Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis	Phase 4	Not yet recruiting	Jay C. Buckey Jr.	100	2026-11-01	2026-09-09
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Almirall, S.A.	230	2026-11-01	2026-10-14
Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen' Karisma - Wrinkle, Scar	Not applicable	Recruiting	Taumedika s.r.l.	40	2026-11-01	2026-10-02
Enhancing the Durability of Thread-Assisted Brow Suspension Through Upper Blepharoplasty-Assisted Ligament Release Upper Blepharoplasty, Barbed Thread Brow Suspension, Lateral Brow-Retaining Ligament Release - Brow Ptosis, Dermatochalasis	Not applicable	Not yet recruiting	Muhammed Mustafa Demirok	90	2026-10-27	2026-10-16
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome	Phase 1	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	20	2026-10-27	2026-10-22
Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis Melatonin, Standard Treatment for Atopic Dermatitis - Atopic Dermatitis	Not applicable	Not yet recruiting	Can Tho University of Medicine and Pharmacy	130	2026-10-10	2026-09-25
A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa	Phase 2	Recruiting	Energenesis Biomedical Co., Ltd.	24	2026-10-08	2026-10-05

Showing 20 of 2384. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (1508)  ·  Eczema (326)  ·  Cutis Laxa (154)  ·  Behcet Syndrome (131)  ·  Dermatitis (90)  ·  Epidermolysis Bullosa (80)  ·  Pruritus (80)  ·  Epidermolysis Bullosa Dystrophica (77)  ·  Psoriasis (77)  ·  Skin Diseases (72)  ·  Ehlers-Danlos Syndrome (64)  ·  Asthma (51)  ·  Hypersensitivity (41)  ·  Cryopyrin-Associated Periodic Syndromes (35)  ·  Food Hypersensitivity (34)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2384)  ·  Skin and Connective Tissue Diseases (2380)  ·  Genetic Diseases, Inborn (2364)  ·  Skin Diseases (2311)  ·  Immune System Diseases (1586)  ·  Hypersensitivity, Immediate (1535)  ·  Hypersensitivity (1523)  ·  Skin Diseases, Eczematous (1492)  ·  Dermatitis (1424)  ·  Congenital Abnormalities (423)  ·  Skin Abnormalities (411)  ·  Connective Tissue Diseases (381)  ·  Pathological Conditions, Signs and Symptoms (299)  ·  Cardiovascular Diseases (263)

Interventions

dupilumab (86)  ·  pimecrolimus (39)  ·  abrocitinib (30)  ·  Tacrolimus (28)  ·  Adrenal Cortex Hormones (26)  ·  upadacitinib (26)  ·  lebrikizumab (25)  ·  Blood Specimen Collection (21)  ·  tralokinumab (20)  ·  crisaborole (19)  ·  Cyclosporine (18)  ·  Ointments (17)  ·  baricitinib (16)  ·  difamilast (14)  ·  canakinumab (12)

Sponsors

Pfizer (59)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (41)  ·  LEO Pharma (37)  ·  Sanofi (36)  ·  AbbVie (32)  ·  Assistance Publique - Hôpitaux de Paris (32)  ·  Novartis Pharmaceuticals (32)  ·  Regeneron Pharmaceuticals (31)  ·  Eli Lilly and Company (29)  ·  Northwestern University (24)  ·  Assiut University (21)  ·  Ulthera, Inc (21)  ·  Amgen (19)  ·  Astellas Pharma Inc (16)  ·  Incyte Corporation (16)

Countries

United States (1043)  ·  Germany (281)  ·  France (256)  ·  Canada (246)  ·  China (215)  ·  United Kingdom (178)  ·  Poland (172)  ·  Spain (157)  ·  Italy (129)  ·  Australia (128)  ·  Japan (126)  ·  Netherlands (105)  ·  South Korea (98)  ·  Czechia (81)  ·  Taiwan (78)

Top investigators

Amy Paller, MD (9)  ·  Robert Bissonnette, MD (8)

Results publications

PMID 39588375, PMID 33826132, PMID 42162528, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40993471, PMID 33165005, PMID 39104653, PMID 40028832, PMID 31066001, PMID 33453450, PMID 34142350, PMID 35061234, PMID 35342978, PMID 35567671, PMID 35636689, PMID 36749121, PMID 36808602, PMID 38777187, PMID 40555305, PMID 41118053, PMID 25006719, PMID 31407311, PMID 31424712, PMID 33658996, PMID 33954933, PMID 33982267, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35462428, PMID 35714786, PMID 35763326, PMID 36152216, PMID 36525340, PMID 36754548, PMID 37043227, PMID 37247226, PMID 37949351, PMID 37988255, PMID 39008191, PMID 39110139, PMID 39441580, PMID 40085349, PMID 40383273

NIH funding

2018 (32), 2023 (22), 2017 (15), 2014 (13), 2016 (12), 2025 (12), 2019 (11), 2015 (6), U54DK083909 (6), 2008 (4), 2009 (4), P30CA015704 (2), R21AR062357 (2), UL1RR024150 (2), 1OT2OD028183-01 (1)